Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/07/22
End: 04/14/22
Due: 04/14/23
Phase: N/A
Priority: Normal
Start: 09/26/23
End: 03/31/25
Due: 03/31/26
Phase: N/A
Priority: Normal
Start: 03/24/21
End: 01/11/22
Due: 01/11/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects | NCT05325346 | Veralox Therapeutics | user2@example.com | None | 2022-03-07 | 2022-04-14 | 2023-04-14 | - | - | 2025-07-14 |
| A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia | NCT05785819 | Veralox Therapeutics | user2@example.com | None | 2023-09-26 | 2025-03-31 | 2026-03-31 | - | - | 2025-07-14 |
| Phase I Study of VLX-1005 in Healthy Subjects | NCT04783545 | Veralox Therapeutics | user2@example.com | None | 2021-03-24 | 2022-01-11 | 2023-01-11 | - | - | 2025-07-14 |